Polycomb group proteins: Navigators of lineage pathways led astray in cancer

Nature Reviews Cancer

Volumn 9, Issue 11, 2009, Pages 773-784

  Bracken, Adrian P ^a   Helin, Kristian ^b  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

POLYCOMB GROUP PROTEIN; TRANSCRIPTION FACTOR; UNTRANSLATED RNA;

CARCINOGENESIS; CELL DIFFERENTIATION; CELL FATE; CELL LINEAGE; CELL MATURATION; GENE CONTROL; GENE EXPRESSION; GENETIC ASSOCIATION; GENOME ANALYSIS; HUMAN; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REPRESSOR GENE; REVIEW; RNA SEQUENCE;

ANIMALS; CELL LINEAGE; GENE EXPRESSION REGULATION; HUMANS; NEOPLASMS; REPRESSOR PROTEINS; RNA, UNTRANSLATED; TRANSCRIPTION FACTORS;

EID: 70350500219     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2736     Document Type: Review

References (180)

1. Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 414, 105-111 (2001).
2. Stingl, J. & Caldas, C. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nature Rev. Cancer 7, 791-799 (2007).
3. Vescovi, A. L., Galli, R. & Reynolds, B. A. Brain tumour stem cells. Nature Rev. Cancer 6, 425-436 (2006).
4. Feinberg, A. P., Ohlsson, R. & Henikoff, S. The epigenetic progenitor origin of human cancer. Nature Rev. Genet. 7, 21-33 (2006).
5. Ohm, J. E. & Baylin, S. B. Stem cell chromatin patterns: an instructive mechanism for DNA hypermethylation? Cell Cycle 6, 1040-1043 (2007).
6. Ben-Porath, I. et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nature Genet. 40, 499-507 (2008).
7. Ohm, J. E. et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nature Genet. 39, 237-242 (2007).
8. Schlesinger, Y. et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nature Genet. 39, 232-236 (2007).
9. Widschwendter, M. et al. Epigenetic stem cell signature in cancer. Nature Genet. 39, 157-158 (2007)
10. Sparmann, A. & van Lohuizen, M. Polycomb silencers control cell fate, development and cancer. Nature Rev. Cancer 6, 846-856 (2006).
11. Pietersen, A. M. & van Lohuizen, M. Stem cell regulation by polycomb repressors: postponing commitment. Curr. Opin. Cell Biol. 20, 201-207 (2008).
12. Boyer, L. A. et al. Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature 441, 349-353 (2006).
13. Bracken, A. P., Dietrich, N., Pasini, D., Hansen, K. H. & Helin, K. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev. 20, 1123-1136 (2006).
14. Lee, T. I. et al. Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 125, 301-313 (2006).
15. Pasini, D., Bracken, A. P., Hansen, J. B., Capillo, M. & Helin, K. The Polycomb Group protein Suz12 is required for embryonic stem cell differentiation. Mol. Cell. Biol. 27, 3769-3779 (2007).
16. Ezhkova, E. et al. Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells. Cell 136, 1122-1135 (2009).
17. Mohn, F. & Schubeler, D. Genetics and epigenetics: stability and plasticity during cellular differentiation. Trends Genet. 25, 129-136 (2009).
18. Mohn, F. et al. Lineage-specific polycomb targets and de novo DNA methylation define restriction and potential of neuronal progenitors. Mol. Cell 30, 755-766 (2008).
19. Oktaba, K. et al. Dynamic regulation by polycomb group protein complexes controls pattern formation and the cell cycle in Drosophila. Dev. Cell 15, 877-889 (2008).
20. Lessard, J. & Sauvageau, G. Bmi-1 determines the proliferative capacity of and leukaemic stem cells. Nature 423, 255-260 (2003).
21. Molofsky, A. V. et al. Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature 425, 962-967 (2003).
22. Park, I. K. et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423, 302-305 (2003).
23. Dietrich, N. et al. Bypass of senescence by the polycomb group protein CBX8 through direct binding to the INK4A-ARF locus. EMBO J. 26, 1637-1648 (2007).
24. Gil, J., Bernard, D., Martinez, D. & Beach, D. Polycomb CBX7 has a unifying role in cellular lifespan. Nature Cell Biol. 6, 67-72 (2004).
25. Gil, J. & Peters, G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nature Rev. Mol. Cell Biol. 7, 667-677 (2006).
26. Bracken, A. P. et al. The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev. 21, 525-530 (2007).
27. Bruggeman, S. W. et al. Ink4a and Arf differentially affect cell proliferation and neural stem cell self-renewal in Bmi1-deficient mice. Genes Dev. 19, 1438-1443 (2005).
28. Chen, H. et al. Polycomb protein Ezh2 regulates pancreatic β-cell Ink4a/Arf expression and regeneration in diabetes mellitus. Genes Dev. 23, 975-985 (2009).
29. Dhawan, S., Tschen, S. I. & Bhushan, A. Bmi-1 regulates the Ink4a/Arf locus to control pancreatic beta-cell proliferation. Genes Dev. 23, 906-911 (2009).
30. Leung, C. et al. Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature 428, 337-341 (2004).
31. Molofsky, A. V., He, S., Bydon, M., Morrison, S. J. & Pardal, R. Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways. Genes Dev. 19, 1432-1437 (2005).
32. Lowe, S. W. & Sherr, C. J. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr. Opin. Genet. Dev. 13, 77-83 (2003).
33. Vire, E. et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439, 871-874 (2006).
34. Mohammad, H. P. et al. Polycomb CBX7 promotes initiation of heritable repression of genes frequently silenced with cancer-specific DNA hypermethylation. Cancer Res. 69, 6322-6330 (2009).
35. Bea, S. et al. BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res. 61, 2409-2412 (2001).
36. Rubio-Moscardo, F. et al. Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood 105, 4445-4454 (2005).
37. van Lohuizen, M. et al. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell 65, 737-752 (1991).
38. Jacobs, J. J. et al. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev. 13, 2678-2690 (1999).
39. Koontz, J. I. et al. Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. Proc. Natl Acad. Sci. USA 98, 6348-6353 (2001).
40. Bachmann, I. M. et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J. Clin. Oncol. 24, 268-273 (2006).
41. Bracken, A. P. et al. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 22, 5323-5335 (2003).
42. Kleer, C. G. et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl Acad. Sci. USA 100, 11606-11611 (2003).
43. Saramaki, O. R., Tammela, T. L., Martikainen, P. M., Vessella, R. L. & Visakorpi, T. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Genes Chromosom. Cancer 45, 639-645 (2006).
44. van Kemenade, F. J. et al. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 97, 3896-3901 (2001).
45. Varambally, S. et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624-629 (2002).
46. Vekony, H. et al. High expression of Polycomb group protein EZH2 predicts poor survival in salivary gland adenoid cystic carcinoma. J. Clin. Pathol. 61, 744-749 (2008).
47. Weikert, S. et al. Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int. J. Mol. Med. 16, 349-353 (2005).
48. Friedman, J. M. et al. The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res. 69, 2623-2629 (2009).
49. Varambally, S. et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322, 1695-1699 (2008).
50. Raaphorst, F. M., Otte, A. P. & Meijer, C. J. Polycomb-group genes as regulators of mammalian lymphopoiesis. Trends Immunol. 22, 682-690 (2001).
51. Ringrose, L. & Paro, R. Polycomb/Trithorax response elements and epigenetic memory of cell identity. Development 134, 223-232 (2007).
52. Kwong, C. et al. Stability and dynamics of polycomb target sites in Drosophila development. PLoS Genet. 4, e1000178 (2008).
53. Ashburner, M. et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nature Genet. 25, 25-29 (2000).
54. Babu, M. M., Luscombe, N. M., Aravind, L., Gerstein, M. & Teichmann, S. A. Structure and evolution of transcriptional regulatory networks. Curr. Opin. Struct. Biol. 14, 283-291 (2004).
55. Blyth, K., Cameron, E. R. & Neil, J. C. The RUNX genes: gain or loss of function in cancer. Nature Rev. Cancer 5, 376-387 (2005).
56. Myatt, S. S. & Lam, E. W. The emerging roles of forkhead box (Fox) proteins in cancer. Nature Rev. Cancer 7, 847-859 (2007).
57. Pearson, J. C., Lemons, D. & McGinnis, W. Modulating Hox gene functions during animal body patterning. Nature Rev. Genet. 6, 893-904 (2005).
58. Robson, E. J., He, S. J. & Eccles, M. R. A PANorama of PAX genes in cancer and development. Nature Rev. Cancer 6, 52-62 (2006).
59. Caretti, G., Di Padova, M., Micales, B., Lyons, G. E. & Sartorelli, V. The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation. Genes Dev. 18, 2627-2638 (2004).
60. Garcia, E., Marcos-Gutierrez, C., del Mar Lorente, M., Moreno, J. C. & Vidal, M. RYBP, a new repressor protein that interacts with components of the mammalian Polycomb complex, and with the transcription factor YY1. EMBO J. 18, 3404-3418 (1999).
61. Barna, M. et al. Plzf mediates transcriptional repression of HoxD gene expression through chromatin remodeling. Dev. Cell 3, 499-510 (2002).
62. Boukarabila, H. et al. The PRC1 Polycomb group complex interacts with PLZF/RARA to mediate leukemic transformation. Genes D e v. 23, 1195-1206 (2009).
63. Hosokawa, H. et al. Regulation of Th2 cell development by Polycomb group gene bmi-1 through the stabilization of GATA3. J. Immunol. 177, 7656-7664 (2006).
64. Trimarchi, J. M., Fairchild, B., Wen, J. & Lees, J. A. The E2F6 transcription factor is a component of the mammalian Bmi1-containing polycomb complex. Proc. Natl Acad. Sci. USA 98, 1519-1524 (2001).
65. Kleinmann, E., Geimer Le Lay, A. S., Sellars, M., Kastner, P. & Chan, S. Ikaros represses the transcriptional response to Notch signaling in T-cell development. Mol. Cell. Biol. 28, 7465-7475 (2008).
66. Chen, X., Hiller, M., Sancak, Y. & Fuller, M. T. Tissue-specific TAFs counteract Polycomb to turn on terminal differentiation. Science 310, 869-872 (2005).
67. Mercer, T. R., Dinger, M. E. & Mattick, J. S. Long non-coding RNAs: insights into functions. Nature Rev. Genet. 10, 155-159 (2009).
68. Pandey, R. R. et al. Kcnq1ot1 antisense noncoding RNA mediates lineage-specific transcriptional silencing through chromatin-level regulation. Mol. Cell 32, 232-246 (2008).
69. Rinn, J. L. et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell 129, 1311-1323 (2007).
70. Terranova, R. et al. Polycomb group proteins Ezh2 and Rnf2 direct genomic contraction and imprinted repression in early mouse embryos. Dev. Cell 15, 668-679 (2008).
71. Zhao, J., Sun, B. K., Erwin, J. A., Song, J. J. & Lee, J. T. Polycomb proteins targeted by a short repeat RNA to the mouse X chromosome. Science 322, 750-756 (2008).
72. Dinger, M. E. et al. Long noncoding RNAs in mouse embryonic stem cell pluripotency and differentiation. Genome Res. 18, 1433-1445 (2008).
73. Khalil, A. M. et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc. Natl Acad. Sci. USA 106, 11667-11672 (2009).
74. Hogg, J. R. & Collins, K. Structured non-coding RNAs and the RNP Renaissance. Curr. Opin. Chem. Biol. 12, 684-689 (2008).
75. Krajewski, W. A., Nakamura, T., Mazo, A. & Canaani, E. A motif within SET-domain proteins binds single-stranded nucleic acids and transcribed and supercoiled DNAs and can interfere with assembly of nucleosomes. Mol. Cell. Biol. 25, 1891-1899 (2005).
76. Akhtar, A., Zink, D. & Becker, P. B. Chromodomains are protein-RNA interaction modules. Nature 407, 405-409 (2000).
77. Bernstein, E. et al. Mouse polycomb proteins bind differentially to methylated histone H3 and RNA and are enriched in facultative heterochromatin. Mol. Cell. Biol. 26, 2560-2569 (2006).
78. Muchardt, C. et al. Coordinated methyl and RNA binding is required for heterochromatin localization of mammalian HP1α. EMBO Rep. 3, 975-981 (2002).
79. Cawley, S. et al. Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs. Cell 11 6, 499-509 (2004).
80. Guttman, M. et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 458, 223-227 (2009).
81. Lefterova, M. I. et al. PPARγ and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale. Genes Dev. 22, 2941-2952 (2008).
82. Nielsen, R. et al. Genome-wide profiling of PPARγ:RXR and RNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipogenesis. Genes D e v. 22, 2953-2967 (2008).
83. Robertson, A. G. et al. Genome-wide relationship between histone H3 lysine 4 mono-and tri-methylation and transcription factor binding. Genome Res. 18, 1906-1917 (2008).
84. Zheng, Y. et al. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 445, 936-940 (2007).
85. Ramsay, R. G. & Gonda, T. J. MYB function in normal and cancer cells. Nature Rev. Cancer 8, 523-534 (2008).
86. Garraway, L. A. & Sellers, W. R. Lineage dependency and lineage-survival oncogenes in human cancer. Nature Rev. Cancer 6, 593-602 (2006).
87. Zhang, S. J. et al. Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia. Proc. Natl Acad. Sci. USA 105, 2076-2081 (2008).
88. Kouros-Mehr, H., Kim, J. W., Bechis, S. K. & Werb, Z. GATA-3 and the regulation of the mammary luminal cell fate. Curr. Opin. Cell Biol. 20, 164-170 (2008).
89. Nerlov, C. The C/EBP family of transcription factors: a paradigm for interaction between gene expression and proliferation control. Trends Cell Biol. 17, 318-324 (2007).
90. Mullighan, C. G. et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453, 110-114 (2008).
91. Nichols, J. et al. Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell 95, 379-391 (1998).
92. Gidekel, S., Pizov, G., Bergman, Y. & Pikarsky, E. Oct-3/4 is a dose-dependent oncogenic fate determinant. Cancer Cell 4, 361-370 (2003).
93. Hochedlinger, K., Yamada, Y., Beard, C. & Jaenisch, R. Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell 121, 465-477 (2005).
94. Reid, A. et al. Leukemia translocation gene, PLZF, is expressed with a speckled nuclear pattern in early hematopoietic progenitors. Blood 86, 4544-4552 (1995).
95. Ivanova, N. B. et al. A stem cell molecular signature. Science 298, 601-604 (2002).
96. Sauvageau, G. et al. Differential expression of homeobox genes in functionally distinct CD34+ subpopulations of human bone marrow cells. Proc. Natl Acad. Sci. USA 91, 12223-12227 (1994).
97. Thorsteinsdottir, U. et al. Overexpression of the myeloid leukemia-associated Hoxa9 gene in bone marrow cells induces stem cell expansion. Blood 99, 121-129 (2002).
98. Lang, D. et al. Pax3 functions at a nodal point in melanocyte stem cell differentiation. Nature 433, 884-887 (2005).
99. Olguin, H. C. & Olwin, B. B. Pax-7 up-regulation inhibits myogenesis and cell cycle progression in satellite cells: a potential mechanism for self-renewal. Dev. Biol. 275, 375-388 (2004).
100. Kotaja, N. & Sassone-Corsi, P. Plzf pushes stem cells. Nature Genet. 36, 551-553 (2004).
101. Villa, R. et al. Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer Cell 11, 513-525 (2007).
102. Nakamura, T. et al. Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukaemia. Nature Genet. 12, 154-158 (1996).
103. Que, J. et al. Multiple dose-dependent roles for Sox2 in the patterning and differentiation of anterior foregut endoderm. Development 134, 2521-2531 (2007).
104. Que, J., Luo, X., Schwartz, R. J. & Hogan, B. L. Multiple roles for Sox2 in the developing and adult mouse trachea. Development 136, 1899-1907 (2009).
105. Chen, X. et al. Multilayered epithelium in a rat model and human Barrett's esophagus: similar expression patterns of transcription factors and differentiation markers. BMC Gastroenterol. 8, 1 (2008).
106. Georgopoulos, K. Haematopoietic cell-fate decisions, chromatin regulation and ikaros. Nature Rev. Immunol. 2, 162-174 (2002).
107. Mullighan, C. G. et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446, 758-764 (2007).
108. Xu, C. R., Schaffer, L., Head, S. R. & Feeney, A. J. Reciprocal patterns of methylation of H3K36 and H3K27 on proximal vs. distal IgVH genes are modulated by IL-7 and Pax5. Proc. Natl Acad. Sci. USA 105, 8685-8690 (2008).
109. Tlsty, T. D. Luminal cells GATA have it. Nature Cell Biol. 9, 135-136 (2007).
110. Gurdon, J. B. & Melton, D. A. Nuclear reprogramming in cells. Science 322, 1811-1815 (2008).
111. Hochedlinger, K. & Plath, K. Epigenetic reprogramming and induced pluripotency. Development 136, 509-523 (2009).
112. Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676 (2006).
113. Deng, J. et al. Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming. Nature Biotechnol. 27, 353-360 (2009).
114. Maherali, N. et al. Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell 1, 55-70 (2007).
115. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
116. Boiani, M. & Scholer, H. R. Regulatory networks in embryo-derived pluripotent stem cells. Nature Rev. Mol. Cell Biol. 6, 872-884 (2005).
117. Wu, H. et al. Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis. Nature 438, 981-987 (2005).
118. Yu, W. et al. Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature 451, 202-206 (2008).
119. Lin, R., Maeda, S., Liu, C., Karin, M. & Edgington, T. S. A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncogene 26, 851-858 (2007).
120. Wang, Z., Gerstein, M. & Snyder, M. RNA-Seq: a revolutionary tool for transcriptomics. Nature Rev. Genet. 10, 57-63 (2009).
121. Zhou, Q. & Melton, D. A. Extreme makeover: converting one cell into another. Cell Stem Cell 3, 382-388 (2008).
122. Nutt, S. L., Heavey, B., Rolink, A. G. & Busslinger, M. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature 401, 556-562 (1999).
123. Laiosa, C. V., Stadtfeld, M., Xie, H., de Andres-Aguayo, L. & Graf, T. Reprogramming of committed T cell progenitors to macrophages and dendritic cells by C/ EBPα and PU.1 transcription factors. Immunity 25, 731-744 (2006).
124. Xie, H., Ye, M., Feng, R. & Graf, T. Stepwise reprogramming of B cells into macrophages. Cell 11 7, 663-676 (2004).
125. Zhou, Q., Brown, J., Kanarek, A., Rajagopal, J. & Melton, D. A. In vivo reprogramming of adult pancreatic exocrine cells to β-cells. Nature 455, 627-632 (2008).
126. Helgeson, B. E. et al. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res. 68, 73-80 (2008).
127. Cardone, M. et al. The novel ETS factor TEL2 cooperates with Myc in B lymphomagenesis. Mol. Cell. Biol. 25, 2395-2405 (2005).
128. Kwei, K. A. et al. Genomic profiling identifies GATA6 as a candidate oncogene amplified in pancreatobiliary cancer. PLoS Genet. 4, e1000081 (2008).
129. Kroon, E., Thorsteinsdottir, U., Mayotte, N., Nakamura, T. & Sauvageau, G. NUP98-HOXA9 expression in hemopoietic stem cells induces chronic and acute myeloid leukemias in mice. EMBO J. 20, 350-361 (2001).
130. Grutz, G. G. et al. The oncogenic T cell LIM-protein Lmo2 forms part of a DNA-binding complex specifically in immature T cells. EMBO J. 17, 4594-4605 (1998).
131. Chervinsky, D. S. et al. Disordered T-cell development and T-cell malignancies in SCL LMO1 double-transgenic mice: parallels with E2A-deficient mice. Mol. Cell. Biol. 19, 5025-5035 (1999).
132. Fisch, P. et al. T-cell acute lymphoblastic lymphoma induced in transgenic mice by the RBTN1 and RBTN2 LIM-domain genes. Oncogene 7, 2389-2397 (1992).
133. Garraway, L. A. et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436, 117-122 (2005).
134. Loercher, A. E., Tank, E. M., Delston, R. B. & Harbour, J. W. MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. J. Cell Biol. 168, 35-40 (2005).
135. Lidonnici, M. R., Corradini, F., Waldron, T., Bender, T. P. & Calabretta, B. Requirement of c-Myb for p210(BCR/ABL)-dependent transformation of hematopoietic progenitors and leukemogenesis. Blood 111, 4771-4779 (2008).
136. Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E. & Bishop, J. M. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224, 1121-1124 (1984).
137. Weiss, W. A., Aldape, K., Mohapatra, G., Feuerstein, B. G. & Bishop, J. M. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J. 16, 2985-2995 (1997).
138. Boon, K., Eberhart, C. G. & Riggins, G. J. Genomic amplification of orthodenticle homologue 2 in medulloblastomas. Cancer Res. 65, 703-707 (2005).
139. Di, C. et al. Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. Cancer Res. 65, 919-924 (2005).
140. Barr, F. G. et al. Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nature Genet. 3, 113-117 (1993).
141. Keller, C. et al. Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ ARF and Trp53 loss of function. Genes Dev. 18, 2614-2626 (2004).
142. Chen, Z. et al. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-α locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO J. 12, 1161-1167 (1993).
143. He, L. Z. et al. Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APL. Nature Genet. 18, 126-135 (1998).
144. Zhang, J., Kalkum, M., Yamamura, S., Chait, B. T. & Roeder, R. G. E protein silencing by the leukemogenic AML1-ETO fusion protein. Science 305, 1286-1289 (2004).
145. Yan, M. et al. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nature Med. 12, 945-949 (2006).
146. Yang, G. et al. Transcriptional repression of the Neurofibromatosis-1 tumor suppressor by the t(8;21) fusion protein. Mol. Cell. Biol. 25, 5869-5879 (2005).
147. O'Neil, J., Shank, J., Cusson, N., Murre, C. & Kelliher, M. TAL1/SCL induces leukemia by inhibiting the transcriptional activity of E47/HEB. Cancer Cell 5, 587-596 (2004).
148. Jacobs, J. J. et al. Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19ARF) and is amplified in a subset of human breast cancers. Nature Genet. 26, 291-299 (2000).
149. Kwei, K. A. et al. Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene 27, 3635-3640 (2008).
150. Weir, B. A. et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 450, 893-898 (2007).
151. Aoki, K., Tamai, Y., Horiike, S., Oshima, M. & Taketo, M. M. Colonic polyposis caused by mTOR-mediated chromosomal instability in Apc+/δ716 Cdx2± compound mutant mice. Nature Genet. 35, 323-330 (2003).
152. Wicking, C. et al. CDX2, a human homologue of Drosophila caudal, is mutated in both alleles in a replication error positive colorectal cancer. Oncogene 17, 657-659 (1998).
153. Chawengsaksophak, K., James, R., Hammond, V. E., Kontgen, F. & Beck, F. Homeosis and intestinal tumours in Cdx2 mutant mice. Nature 386, 84-87 (1997).
154. Bai, Y. Q., Miyake, S., Iwai, T. & Yuasa, Y. CDX2, a homeobox transcription factor, upregulates transcription of the p21/WAF1/CIP1 gene. Oncogene 22, 7942-7949 (2003).
155. Pabst, T. et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia. Nature Genet. 27, 263-270 (2001).
156. Kirstetter, P. et al. Modeling of C/EBPα mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells. Cancer Cell 13, 299-310 (2008).
157. Zuo, T. et al. FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. J. Clin. Invest. 11 7, 3765-3773 (2007).
158. Zuo, T. et al. FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell 129, 1275-1286 (2007).
159. Kouros-Mehr, H., Slorach, E. M., Sternlicht, M. D. & Werb, Z. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell 127, 1041-1055 (2006).
160. Usary, J. et al. Mutation of GATA3 in human breast tumors. Oncogene 23, 7669-7678 (2004).
161. Pei, X. H. et al. CDK inhibitor p18INK4c is a downstream target of GATA3 and restrains mammary luminal progenitor cell proliferation and tumorigenesis. Cancer Cell 15, 389-401 (2009).
162. Raman, V. et al. Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature 405, 974-978 (2000).
163. Garkavtsev, I. et al. The candidate tumour suppressor p33ING1 cooperates with p53 in cell growth control. Nature 391, 295-298 (1998).
164. Maestro, R. et al. Chromosome 13q deletion mapping in head and neck squamous cell carcinomas: identification of two distinct regions of preferential loss. Cancer Res. 56, 1146-1150 (1996).
165. Kichina, J. V. et al. Targeted disruption of the mouse ing1 locus results in reduced body size, hypersensitivity to radiation and elevated incidence of lymphomas. Oncogene 25, 857-866 (2006).
166. Narla, G. et al. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science 294, 2563-2566 (2001).
167. Kimmelman, A. C. et al. Suppression of glioblastoma tumorigenicity by the Kruppel-like transcription factor KLF6. Oncogene 23, 5077-5083 (2004).
168. Huang, X., Li, X. & Guo, B. KLF6 induces apoptosis in prostate cancer cells through up-regulation of ATF3. J. Biol. Chem. 283, 29795-29801(2008).
169. Mueller, B. U. et al. Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood 101, 2074 (2003).
170. Vangala, R. K. et al. The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia. Blood 101, 270-277 (2003).
171. Steidl, U. et al. Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells. Nature Genet. 38, 1269-1277 (2006).
172. Rosenbauer, F. et al. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nature Genet. 36, 624-630 (2004).
173. Li, Q. L. et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109, 113-124 (2002).
174. Ito, K. et al. RUNX3 attenuates β-catenin/T cell factors in intestinal tumorigenesis. Cancer Cell 14, 226-237 (2008).
175. Hahn, S. A. et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271, 350-353 (1996).
176. Izeradjene, K. et al. KrasG12D and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell 11, 229-243 (2007).
177. Haber, D. A. et al. An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor. Cell 61, 1257-1269 (1990).
178. Yang, L., Han, Y., Suarez Saiz, F. & Minden, M. D. A tumor suppressor and oncogene: the WT1 story. Leukemia 21, 868-876 (2007).
179. Englert, C., Maheswaran, S., Garvin, A. J., Kreidberg, J. & Haber, D. A. Induction of p21 by the Wilms' tumor suppressor gene WT1. Cancer Res. 57, 1429-1434 (1997).
180. Bass, A. J. et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nature Genet. 4 Oct 2009 (doi:10.1038/ ng.465).